61,443 Shares in CRISPR Therapeutics AG $CRSP Purchased by NTV Asset Management LLC

NTV Asset Management LLC bought a new position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) in the third quarter, Holdings Channel reports. The firm bought 61,443 shares of the company’s stock, valued at approximately $3,399,000.

A number of other institutional investors have also recently bought and sold shares of CRSP. Versant Capital Management Inc raised its position in shares of CRISPR Therapeutics by 175.1% during the 2nd quarter. Versant Capital Management Inc now owns 465 shares of the company’s stock valued at $25,000 after acquiring an additional 296 shares during the last quarter. Ameritas Advisory Services LLC acquired a new stake in shares of CRISPR Therapeutics during the second quarter worth $56,000. Hollencrest Capital Management grew its stake in shares of CRISPR Therapeutics by 249.9% during the first quarter. Hollencrest Capital Management now owns 1,312 shares of the company’s stock worth $62,000 after purchasing an additional 937 shares during the period. GAMMA Investing LLC grew its stake in shares of CRISPR Therapeutics by 92.0% during the third quarter. GAMMA Investing LLC now owns 1,246 shares of the company’s stock worth $69,000 after purchasing an additional 597 shares during the period. Finally, Thurston Springer Miller Herd & Titak Inc. increased its holdings in CRISPR Therapeutics by 184.2% in the second quarter. Thurston Springer Miller Herd & Titak Inc. now owns 1,637 shares of the company’s stock valued at $89,000 after purchasing an additional 1,061 shares during the last quarter. Institutional investors and hedge funds own 69.20% of the company’s stock.

CRISPR Therapeutics Trading Down 1.2%

CRSP opened at $49.39 on Friday. The firm’s fifty day moving average is $54.60 and its two-hundred day moving average is $53.28. The firm has a market cap of $4.78 billion, a PE ratio of -10.38 and a beta of 1.76. CRISPR Therapeutics AG has a twelve month low of $44.12 and a twelve month high of $68.71. The company has a debt-to-equity ratio of 0.34, a quick ratio of 17.85 and a current ratio of 17.85.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Tuesday, June 30th. The company reported ($0.94) earnings per share (EPS) for the quarter. CRISPR Therapeutics had a negative net margin of 3,368.72% and a negative return on equity of 24.39%. The firm had revenue of $10.18 million during the quarter. Equities research analysts anticipate that CRISPR Therapeutics AG will post -4.44 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on CRSP. William Blair raised CRISPR Therapeutics to a “strong-buy” rating in a research note on Wednesday, September 23rd. Needham & Company LLC restated a “buy” rating and set a $82.00 target price on shares of CRISPR Therapeutics in a report on Monday, August 31st. UBS Group assumed coverage on CRISPR Therapeutics in a research report on Thursday, October 15th. They set a “neutral” rating and a $52.00 target price for the company. Wall Street Zen raised CRISPR Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Finally, Citigroup reaffirmed a “market outperform” rating on shares of CRISPR Therapeutics in a research note on Monday, September 28th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $65.75.

Insiders Place Their Bets

In other news, General Counsel James Kasinger sold 10,400 shares of CRISPR Therapeutics stock in a transaction dated Tuesday, September 22nd. The stock was sold at an average price of $60.24, for a total transaction of $626,496.00. Following the transaction, the general counsel owned 94,784 shares in the company, valued at $5,709,788.16. The trade was a 9.89% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Ali Behbahani sold 13,679 shares of CRISPR Therapeutics stock in a transaction dated Thursday, September 17th. The shares were sold at an average price of $57.09, for a total value of $780,934.11. Following the transaction, the director owned 16,637 shares in the company, valued at $949,806.33. This trade represents a 45.12% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 93,558 shares of company stock valued at $4,881,663. Insiders own 5.20% of the company’s stock.

CRISPR Therapeutics Profile

CRISPR Therapeutics AG (NASDAQ: CRSP) is a biotechnology company focused on developing transformative gene-based medicines using CRISPR/Cas9 gene-editing technology. The company’s research programs are designed to address genetic diseases by precisely modifying DNA in cells, with applications across hematology, immunology, oncology, regenerative medicine and cardiovascular disease.

Its lead commercial product is CASGEVY, an autologous cell therapy developed in collaboration with Vertex Pharmaceuticals.